Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy

Zhiqiu Ye 1 · Zhizhen Deng 1,2 · Suxiang Jiang 3 · Tang Wang 3 · Long Liu 3 · Kuiming Jiang 1 · Yingqiang Zhang 3

Received: 8 December 2020 / Accepted: 12 April 2021 / Published online: 4 May 2021 © The Author(s) 2021

Abstract

Purpose The survival benefits of patients with inoperable hepatocellular carcinoma (HCC) who undergo transarterial chemoembolization (TACE) and receive sorafenib therapy remain controversial. We aimed to identify clinical predictors in patients with inoperable HCC undergoing TACE and receiving sorafenib.

Methods Between January 2014 and December 2017, 148 consecutive patients with inoperable HCC who were treated with TACE plus sorafenib were retrospectively analyzed. Critical clinical factors associated with overall survival (OS) were identified by Cox regression model analysis. Kaplan–Meier methods were used to calculate the survival times, which were compared with the log-rank test.

Results Macrovacular invasion (MVI), radiologic response and sorafenib-related dermatologic toxicities were identified as independent factors associated with OS. MVI is a known prognostic factor before treatment. The median OS of patients with either radiologic response or dermatologic toxicities was significantly improved compared with that of patients without it (both 23.0 vs. 7.0 months, P < 0.001). The median OS of patients with a combination of radiologic response and dermatologic toxicities was significantly longer than that of patients with either radiologic response or dermatologic toxicities, as well as no response (25.0 vs. 14.0 vs. 6.0 months, respectively, P < 0.001), and the predictive value was confirmed across patients with different baseline characteristics in terms of MVI, α-fetoprotein level, performance status and liver function.

Conclusion The combination of radiologic response and sorafenib-related dermatologic toxicities is the most robust predictor of survival benefits for HCC patients after TACE plus sorafenib therapy.

Level of Evidence Level 3.

Keywords Hepatocellular carcinoma · Transarterial chemoembolization · Sorafenib · Survival · Predictor

Introduction

Approximately half of hepatocellular carcinoma (HCC) cases are diagnosed at an inoperable stage. The treatment options for inoperable HCC are limited, and the prognosis is dismal [1–3]. Based on the evidence of current HCC...
guidelines, transarterial chemoembolization (TACE) is a common and valuable local therapy for inoperable HCC [1–3]. However, the long-term efficacy of TACE alone remains unsatisfactory due to large tumor load or macrovascular invasion (MVI) [4, 5]. Sorafenib, an oral multikinase inhibitor, is the first approved targeted agent for advanced HCC; it targets vascular endothelial growth factor receptor (VEGFR)-1, 2 and 3, platelet-derived growth factor receptor (PDGFR)-α and β, and serine-threonine kinases (Raf-1 and B-Raf) involved in tumor cell proliferation and tumor angiogenesis [6, 7]. The toxicities related to sorafenib include fatigue, weight loss, diarrhea, anorexia, nausea, vomiting, and hypertension, as well as dermatologic toxicities including rash, desquamation, pruritus, erythema, alopecia, and hand-foot skin reaction (HFSR) [8]. HFSR is a cutaneous reaction characterized by erythema, numbness, tingling, and dysesthesia or paresthesia, particularly on the palms and soles. Some severe cases may present edema, peeling, bleeding, blistering, or ulceration [9].

Previously, several authors have suggested that TACE plus sorafenib may be a “good combination” for inoperable HCC [10, 11]. Several observational studies have demonstrated that TACE plus sorafenib produces additional survival benefits compared with TACE or sorafenib monotherapy for patients with inoperable HCC [12–15]. However, the STAH trial showed no overall survival (OS) benefits in patients with advanced HCC who underwent TACE plus sorafenib compared with those who received sorafenib alone (OS 12.8 months vs. 10.8 months, \( P = 0.290 \)) [16]. Conversely, a large nationwide cohort study in Taiwan showed that TACE plus sorafenib improved survival benefits compared with TACE alone in advanced HCC (OS 381 days vs. 204 days, \( P = 0.021 \)) [17]. Additionally, the TACE2 trial showed that drug-eluting beads (DEB-TACE) combined with sorafenib did not improve the progression-free survival (PFS) compared with DEB-TACE plus placebo (PFS 238 days vs. 235 days, \( P = 0.94 \)) in European patients with unresectable HCC [18]; while the TACTICS trial showed that TACE plus sorafenib significantly improve the PFS compared with TACE alone in Asian patients with unresectable HCC (PFS 25.2 months vs. 13.5 months, \( P = 0.006 \)) [19]. Thus, the survival benefits from TACE plus sorafenib remain controversial, and the predictors associated with survival benefits remain unclear.

To date, there have been no definite clinical factors or plasma biomarkers before treatment that can predict survival benefits, and only prognostic factors have been identified, such as MVI, performance status, and alphafetoprotein level, which are well-known prognostic factors for HCC patients regardless of whether they receive local regional or systemic therapies [12, 14, 20]. Thus, these prognostic factors may have little clinical value for identifying the survival benefits of HCC patients who receive TACE plus sorafenib. Therefore, this study aimed to: (a) investigate the significant predictors of survival benefits in a cohort of inoperable HCC patients after TACE plus sorafenib therapy, and (b) identify the robust predictors of survival for these patients.

Materials and Methods

Study Population

From January 2014 to December 2017, the electronic medical records of HCC patients who received TACE plus sorafenib in our center were retrospectively reviewed. The protocol was approved by the ethics committee of the institutional review board.

The inclusion criteria were as follows: (a) diagnosis of inoperable HCC according to pathology or radiology results (contrast-enhanced computed tomography [CT] or magnetic resonance imaging [MRI]) based on the Chinese guideline for Liver Cancer [3]; (b) macrovascular invasion diagnosed on images, presented as an HCC tumor invading the adjacent portal vein or hepatic vein with a low-attenuation intraluminal venous mass [21, 22]; (c) age 18–75 years; (d) Child–Pugh score less than 8; and (e) Eastern Cooperative Oncology Group (ECOG) score less than 2.

The exclusion criteria were as follows: (a) patients with main portal vein invasion; (b) patients in whom the duration of sorafenib treatment was less than 1 month; (c) patients with serious diseases, for example, jaundice, massive ascites, or other heart or pulmonary diseases; (d) patients with a previous malignancy; and (e) patients who previously received liver surgery or other treatments for HCC.

Treatment

The treatment protocol was performed as previously described [21, 23]. First, using the Seldinger technique to puncture the femoral artery, a 5 Fr catheter was introduced to the celiac trunk and superior mesenteric artery, and angiography was performed to evaluate the tumor blood supply and to assess the flow of the portal vein. Then, superselective catheterization was performed using a microcatheter to the tumor feeding artery. Next, an emulsion was created using 10–20 mL of Lipiodol (Guerbet, Paris, France) mixed with 20–40 mg of epirubicin (Pfizer, New York, USA). Based on the tumor load, the emulsion was injected into the tumor feeding artery via microcatheter. When the emulsion slowed or backflowed, the injection was stopped, with a maximum volume of no more
Dermatologic toxicities were defined as the presentation of skin changes (e.g., grade ≥ 2) within the first month of sorafenib therapy. Toxicities were evaluated by an attending physician (with at least 5 years of experience in oncology) according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grade of dermatologic toxicities is listed in Appendix Table 1.

Statistical Analysis

For the baseline characteristics, continuous variables are described as the mean ± standard deviation, and categorical variables are expressed as the number and percentage of patients. OS was calculated by the Kaplan–Meier method and compared using the log-rank test. A univariate analysis was used for all studied variables, and the results were compared using the log-rank test. Variables with \( P < 0.1 \) in the univariate analysis were entered into a multivariate Cox analysis, which was used to identify risk factors that independently affected OS. All statistical tests were two-sided, and \( P < 0.05 \) was considered statistically significant. All statistical analyses were performed with SPSS software (SPSS version 16.0, Chicago, IL, USA).

Results

Demographics

A total of 148 consecutive patients with inoperable HCC treated with TACE plus sorafenib during the study period were considered in the analysis (Fig. 1). The demographics of the cohort are shown in Table 1. Briefly, the mean tumor size among patients was 8.2 cm. Hepatitis B and liver cirrhosis were the most common diseases. Forty-five percent (\( n = 67 \)) of the patients had Barcelona Clinic Liver Cancer (BCLC) stage B cancer, while the remaining 55% (\( n = 81 \)) of patients had BCLC stage C cancer; among these, 81 showed MVI and 8 showed extrahepatic spread.

Treatment Outcome

The mean number of TACE sessions per patient was 3.5 (range 2–6). The median duration of sorafenib therapy was 8 months (range 1–50 months). At 1 month post-treatment, the imaging data were assessed for all patients: fourteen patients (9.5%) had CR, 54 (36.5%) had PR, 16 (10.8%) had SD, and 64 (43.2%) had PD. Accordingly, the radiologic response rate was 45.9%. No patients in the present series underwent subsequent liver surgery. Additionally, a total of 105 patients (70.9%) experienced sorafenib-related toxicities within the first month of sorafenib treatment, and the most frequent toxicities were hand-foot-skin reactions,
alopecia, weight loss and diarrhea. Among these patients, 76 (51.4%) were documented as having dermatologic toxicities. The most frequent complication related to TACE was post-embolization syndrome. A detailed list of the side effects related to the combination therapy is shown in appendix Table 2.

### Survival Analysis

Overall, 138 patients (93.2%) died and were censored from follow-up. The median follow-up for these patients was 17.9 months (range 3–63). The median OS for the overall cohort was 13.0 months (95% CI 10.2, 15.8).

In the univariate analysis, the following variables were significantly associated with OS: number of tumors, α-fetoprotein level, ECOG performance status, MVI, radiologic response and dermatologic toxicities. The multivariate analysis demonstrated that MVI, dermatologic toxicities and radiologic response were independent factors for OS (Table 2).

MVI is a well-known prognostic factor for poor prognosis, and the median OS in this study was 18.0 and 8.0 months for patients without and with MVI, respectively ($P < 0.001$). The median OS was 23.0 months for patients with a radiologic response and 7.0 months for patients without a radiologic response ($P < 0.001$) (Fig. 2A). The median OS was 23.0 and 7.0 months for patients with and without dermatologic toxicities ($P < 0.001$), respectively (Fig. 2B). The median OS values for patients with a radiologic response and for patients with dermatologic toxicities were comparable.
Table 2  Univariate and multivariate analysis of prognostic factors

| Variable               | Univariate analysis | Multivariate analysis |
|------------------------|--------------------|-----------------------|
|                        | Median OS (mos)    | 95% CI                | P value | Hazard ratio | 95% CI | P value |
| Age (years)            |                    |                      |         |              |        |         |
| < 52                   | 9.0                | 5.9, 12.1             | 0.088   | 0.803        | 0.560, 1.154 | 0.236 |
| ≥ 52                   | 18.0               | 13.3, 22.7            |         | 1.000        |        |         |
| Number of tumors       | < 0.001            |                      |         |              |        |         |
| ≤ 5                    | 19.0               | 16.7, 21.3            |         | 1.025        | 0.686, 1.532 | 0.904 |
| > 5                    | 9.0                | 6.6, 11.4             |         | 1.000        |        |         |
| MVI                    | < 0.001            |                      |         |              |        |         |
| Present                | 18.0               | 10.5, 25.5            |         | 1.000        |        |         |
| Absent                 | 8.0                | 6.6, 9.4              |         | 1.989        | 1.255, 3.151 | 0.904 |
| AFP level (ng/mL)      |                    |                      |         |              |        |         |
| < 400                  | 23.0               | 18.9, 27.1            |         | 0.847        | 0.547, 1.312 | 0.457 |
| ≥ 400                  | 10.0               | 7.7, 12.4             |         | 1.000        |        |         |
| ECOG score             | 0.001              |                      |         |              |        | 0.218 |
| 0–1                    | 14.0               | 11.1, 16.9            |         | 1.000        |        |         |
| 2                      | 7.0                | 4.4, 9.6              |         | 1.654        | 0.743, 3.685 | 0.475 |
| Radiologic response*   | < 0.001            |                      |         |              |        |         |
| Responders             | 23.0               | 19.7, 26.3            |         | 1.000        |        |         |
| Nonresponders          | 7.0                | 5.8, 8.2              |         | 3.549        | 2.136, 5.898 | 0.218 |
| Dermatologic toxicities| < 0.001            |                      |         |              |        |         |
| Present                | 23.0               | 20.2, 25.8            |         | 1.000        |        |         |
| Absent                 | 7.0                | 6.1, 7.9              |         | 8.074        | 4.752, 13.7185 | 0.001 |

*Responders indicates complete response or partial response; nonresponders indicates stable disease or progressive disease. AFP alpha-feto-protein, ECOG Eastern Cooperative Oncology Group, MVI macrovascular invasion, CI confidence interval, OS overall survival

Fig. 2 Kaplan–Meier curves showing overall survival (OS) for patients with inoperable hepatocellular carcinoma treated with sorafenib plus transarterial chemoembolization. A The median OS for patients with and without a radiologic response was 23.0 months and 7.0 months, respectively (P < 0.001). B The median OS for patients with and without the presence of dermatologic toxicities was 23.0 months and 7.0 months, respectively (P < 0.001)
Survival Stratification

Based on the results of this study, radiologic response and dermatologic toxicities were critical predictors of a favorable prognosis. Therefore, three groups were identified based on radiologic response and dermatologic toxicities: patients with both radiologic response and dermatologic toxicities, patients with either radiologic response or dermatologic toxicities, and patients without radiologic response or dermatologic toxicities (hereafter referred to as group A, group B, and group C, respectively). The median survival in the overall cohort for group A, B and C was 25.0, 14.0, and 6.0 months, respectively \((P < 0.001)\) (Fig. 3). To validate the predictive value of the combination of radiologic response and dermatologic toxicities across the overall cohort, a subgroup survival analysis of the relevant pretreatment baseline characteristics was conducted, which included MVI, \(\alpha\)-fetoprotein level, Child–Pugh class, and ECOG performance status.

The median OS for patients with MVI in group A, B, and C was 18.0, 14.0, and 6.0 months, respectively \((P < 0.001)\). The median OS for patients without MVI in group A, B, and C was 32.0, 19.0, and 6.0 months, respectively \((P < 0.001)\) (Fig. 4A, B).

The median OS for patients with \(\alpha\)-fetoprotein \(\leq 400\) ng/mL in group A, B, and C was 30.0, 22.0, and 5.0 months, respectively \((P < 0.001)\). The median OS for patients with \(\alpha\)-fetoprotein > 400 ng/mL in group A, B, and C was 21.0, 14.0, and 6.0 months, respectively \((P < 0.001)\).

Discussion

The present study focused on inoperable HCC patients and showed a median survival of 13.0 months, which is comparable to that reported in previous studies of patients with advanced HCC who received sorafenib plus TACE therapy [16, 17, 20]. Overall, the survival rate was better than that in the Asia–Pacific trial, in which patients received sorafenib monotherapy (median OS 6.5 months) [7]. In terms of clinical impact, this study mainly aimed to identify robust predictors of favorable survival. After the final Cox analysis, radiologic response and dermatologic toxicities were found to be independent predictors of survival in patients with inoperable HCC treated with TACE plus sorafenib.

Radiologic assessment plays a critical role in evaluating treatment efficacy and predicting the survival of HCC patients [23–25]. Currently, tumor response assessment mainly includes an evaluation of the initial response and the best response. The best response was defined as the best radiologic response across all time points during repeated “on-demand” sessions. Both the initial response and the best response predict OS well [26]. However, the optimal number of TACE sessions needed to reach the best response in an individual remains unpredictable; consequently, there has been controversy regarding the best time point to evaluate the treatment response after each TACE session for an accurate prediction of OS [28]. Another merit of the initial response is the high follow-up rate. Several studies have demonstrated that the initial radiologic response is a robust predictor of survival [26, 27], which was confirmed by our results.

Sorafenib-related dermatologic toxicities are an important predictor of the treatment response and survival of patients with HCC who undergo sorafenib therapy [9]. Several studies have indicated that dermatologic toxicities are an early biomarker for the prognosis of patients with HCC treated with sorafenib [29–31]. However, the underlying relationship between dermatologic toxicities and treatment response remains unclear, and there are no definite plasma biomarkers that predict these responses [32].
In the present study, the median OS of patients with dermatologic toxicities was significantly higher than that of patients without dermatologic toxicities, which was in line with previous results.

In this study, we attempted to identify the most robust predictor of survival in patients with inoperable HCC receiving TACE plus sorafenib. After the final survival analysis, we found that the combination of radiologic response and dermatologic toxicities was a better predictor of favorable prognosis than either radiologic response or dermatologic toxicities alone, and the predictive value was confirmed across subgroups of patients with different baseline characteristics in terms of MVI, α-fetoprotein level, performance status and liver function. Thus, we believe that the presence of both radiologic response and dermatologic toxicities is the most robust predictor associated with the response to TACE plus sorafenib. A likely explanation is that a radiologic response mainly reflects the efficacy of TACE, while dermatologic toxicities mainly reflect the response to sorafenib. Therefore, the combined presence of radiologic response and dermatologic toxicities predicts the greatest survival benefits for HCC patients who receive TACE plus sorafenib. Recently, a prognostic score model indicated that performance status, portal vein tumor thrombus, radiologic response and dermatologic toxicity could accurately predict survival for patients with HCC undergoing sorafenib plus TACE, and these findings were confirmed by our results [31]. Therefore, based on our results, we believe that inoperable HCC patients, regardless of the presence of MVI or high α-fetoprotein level, may achieve survival benefits after TACE plus sorafenib. Unfortunately, there were no definite factors to predict the response before treatment, especially regarding sorafenib-related dermatologic toxicities. Thus, the discordance of results regarding survival benefits between randomized control trials (for example, the STAH and TACE2 trials) [16, 18] and retrospective observational studies [12–15, 17] may be addressed using our results. It is known that retrospective observational studies have potential selection bias (i.e., patients with longer survival times may have a longer duration of sorafenib treatment).

This study has some limitations. First, it is a retrospective study with a relatively small sample size. Second, although sorafenib-related dermatologic toxicities were identified as a robust predictor of survival benefits, no definitive factors were identified to accurately predict the response before treatment. Nevertheless, this predictor may be helpful for identifying whether a patient might benefit from sorafenib and for decision-making regarding whether to continue therapy after the first cycle of treatment.

In conclusion, the results of this study suggest that radiologic response and sorafenib-related dermatologic toxicities are critical predictors of favorable survival in HCC patients after TACE plus sorafenib. The combined presence of both radiologic response and dermatologic toxicities performed better than the presence of radiologic response or dermatologic toxicities alone in predicting the survival benefits for these patients.

Fig. 4 Response-based stratification of the survival of patients with or without presentation of macrovascular invasion (MVI). A The median survival values for patients with MVI in the groups with both radiologic response and dermatologic toxicities, either radiologic response or dermatologic toxicities, and no response were 18.0 months, 14.0 months, and 6.0 months, respectively (P < 0.001). B The median OS for patients without MVI in the groups with both radiologic response and dermatologic responses, either radiologic response or dermatologic toxicities, and no response was 32.0 months, 19.0 months, and 6.0 months, respectively (P < 0.001)
References

1. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice guideline by the American Association for the study of liver diseases. Hepatology. 2018;68:723–50.
2. EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.
3. Zhou J, Sun HC, Wang Z, et al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer. 2018;7:235–60.
4. Lau WY, Yu SC, Lai EC, Leung TW. Transarterial chemoembolization for hepatocellular carcinoma. J Am Coll Surg. 2006;202:155–68.
5. Sieghart W, Huckle F, Peck-R M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62:1187–95.
6. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.
7. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.
8. Kane RC, Farrell AT, Madabushi R, et al. Sorafenib for the treatment of unresectable hepatocellular carcinoma. Oncologist. 2009;14:95–100.
9. Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85–92.
10. Abou-Alfa GK. TACE and sorafenib: a good marriage? J Clin Oncol. 2011;29:3949–52.
11. Dufour JF. TACE with or without systemic therapy? J Hepatol. 2012;56:1224–5.
12. Zhu K, Chen J, Lai L, et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—a retrospective controlled study. Radiology. 2014;272:284–93.
13. Li J, Zhang F, Yang J, et al. Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study. Target Oncol. 2015;10:287–95.
14. Zhu K, Huang J, Lai L, et al. Medium or large hepatocellular carcinoma: sorafenib combined with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018;288:300–7.
15. Peng Z, Chen S, Wei M, et al. Advanced recurrent hepatocellular carcinoma: treatment with sorafenib alone or in combination with transarterial chemoembolization and radiofrequency ablation. Radiology. 2018:287:705–14.
16. Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemobembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol. 2019;70:684–91.
17. Kok VC, Chen YC, Chen YY, et al. Sorafenib with transarterial chemoembolization achieves improved survival vs. sorafenib alone in advanced hepatocellular carcinoma: a nationwide population-based cohort study. Cancers. 2019;11:985.
18. Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE2): a randomized placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:565–75.
19. Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre, prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020;69:1492–501.
20. Zhao Y, Wang WJ, Guan S, et al. Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients. Ann Oncol. 2013;24:1786–92.
21. Zhang Y, Fan W, Wang Y, et al. Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis. Oncologist. 2015;20:1417–24.
22. Spredaico C, Sposito C, Vaiani M, et al. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion. J Hepatol. 2018;68:724–32.
23. Zhang YQ, Jiang LJ, Wen J, et al. Comparison of α-fetoprotein criteria and modified response evaluation criteria in solid tumors for the prediction of overall survival of patients with hepatocellular carcinoma after transarterial chemoembolization. J Vasc Interv Radiol. 2018;29:1654–61.
24. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52–60.
25. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303:1062–9.
26. Kim BK, Kim SU, Kim KA, et al. Complete response at first chemoembolization is still the most robust predictor for favourable outcome in hepatocellular carcinoma. J Hepatol. 2015;62:1304–10.
27. Kim CJ, Kim HJ, Park JH, et al. Radiologic response to trans-catheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int. 2014;34:305–12.

28. Wang W, Zhao Y, Bai W, Han G. Response assessment for HCC patients treated with repeated TACE: the optimal time-point is still an open issue. J Hepatol. 2015;63:1530–1.

29. Zhao Y, Li H, Bai W, et al. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: a multicenter clinical study of 606 HCC patients. Int J Cancer. 2016;139:928–37.

30. Zhong BY, Ni CF, Chen L, Zhu HD, Teng GJ. Early sorafenib-related biomarkers for combination treatment with transarterial chemoembolization and sorafenib in patients with hepatocellular carcinoma. Radiology. 2017;284:583–92.

31. Zhang Y, Miao H, Xie W, et al. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. Eur Radiol. 2021;31:232–43.

32. Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18:2290–300.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.